A dominant-negative p65 PAK peptide inhibits angiogenesis

被引:116
|
作者
Kiosses, WB
Hood, J
Yang, SY
Gerritsen, ME
Cheresh, DA
Alderson, N
Schwartz, MA
机构
[1] Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA
[3] Genentech Inc, Dept Cardiovasc Res, San Francisco, CA USA
关键词
endothelial cells; p21-activated kinase; cell contractility; endothelial tube-forming assay;
D O I
10.1161/01.RES.0000014227.76102.5D
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PAK1 is a protein kinase downstream of the small GTPases Rac and Cdc42 that previous work has implicated in endothelial cell migration via modulation of cell contraction. The first proline-rich region of PAK that binds to an SH3 domain from the adapter protein NCK was responsible for these dominant-negative effects. To test the role of PAK in angiogenesis, we prepared a peptide in which the proline-rich region was fused to the polybasic sequence from the HIV Tat protein to facilitate entry into cells. We show that the short peptide selectively binds NCK, whereas a mutant peptide does not. Treatment of cells with the PAK peptide but not the control peptide disrupts localization of PAK. This peptide specifically inhibited endothelial cell migration and contractility similarly to full-length dominant-negative PAK. In an in vitro tube-forming assay, the PAK peptide specifically blocked formation of multicellular networks. In an in vivo chick chorioallantoic membrane assay, the PAK peptide specifically blocked angiogenesis. These results, therefore, suggest a role for PAK in angiogenesis.
引用
收藏
页码:697 / 702
页数:6
相关论文
共 50 条
  • [41] Dominant-negative c-Jun inhibits rat cardiac hypertrophy induced by angiotensin II and hypertension
    S Kim-Mitsuyama
    Y Izumi
    Y Izumiya
    M Namba
    K Yoshida
    R Wake
    M Yoshiyama
    H Iwao
    Gene Therapy, 2006, 13 : 348 - 355
  • [42] A Dominant-Negative FGF1 Mutant (the R50E Mutant) Suppresses Tumorigenesis and Angiogenesis
    Mori, Seiji
    Vu Tran
    Nishikawa, Kyoko
    Kaneda, Teruya
    Hamada, Yoshinosuke
    Kawaguchi, Naomasa
    Fujita, Masaaki
    Takada, Yoko K.
    Matsuura, Nariaki
    Zhao, Min
    Takada, Yoshikazu
    PLOS ONE, 2013, 8 (02):
  • [43] Regression/Eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide
    Cates, Charles C.
    Arias, Angelo D.
    Wong, Lynn S. Nakayama
    Lame, Michael W.
    Sidorov, Maxim
    Cayanan, Geraldine
    Rowland, Douglas J.
    Fung, Jennifer
    Karpel-Massler, Georg
    Siegelin, Markus D.
    Greene, Lloyd A.
    Angelastro, James M.
    ONCOTARGET, 2016, 7 (11) : 12718 - 12730
  • [44] The dominant-negative interplay between p53, p63 and p73: A family affair
    Billant, Olivier
    Leon, Alice
    Le Guellec, Solenn
    Friocourt, Gaelle
    Blondel, Marc
    Voisset, Cecile
    ONCOTARGET, 2016, 7 (43) : 69549 - 69564
  • [45] Dominant-negative inactivation of p53:: The effect of the proportion between a trans-dominant inhibitor and its target
    Morgunkova, AA
    Almazov, VP
    Strunina, SM
    Kopnin, BP
    Chumakov, PM
    MOLECULAR BIOLOGY, 2003, 37 (01) : 102 - 109
  • [46] Dominant-Negative Inactivation of p53: The Effect of the Proportion between a Trans-Dominant Inhibitor and Its Target
    A. A. Morgunkova
    V. P. Almazov
    S. M. Strunina
    B. P. Kopnin
    P. M. Chumakov
    Molecular Biology, 2003, 37 : 102 - 109
  • [47] Negative regulation of NF-κB p65 activity by serine 536 phosphorylation
    Pradere, Jean-Philippe
    Hernandez, Celine
    Koppe, Christiane
    Friedman, Richard A.
    Luedde, Tom
    Schwabe, Robert F.
    SCIENCE SIGNALING, 2016, 9 (442)
  • [48] Retroviral delivery of dominant-negative vascular endothelial growth factor receptor type 2 to murine wounds inhibits wound angiogenesis (vol 10, pg 222, 2002)
    Tsou, R
    Fathke, C
    Wilson, L
    Wallace, K
    Gibran, N
    Isik, F
    WOUND REPAIR AND REGENERATION, 2002, 10 (06) : 409 - 409
  • [49] Dominant-negative p53 mutations selected in yeast hit cancer hot spots
    Brachmann, RK
    Vidal, M
    Boeke, JD
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (09) : 4091 - 4095
  • [50] DOMINANT-NEGATIVE AGGREGATION OF P53 AS A NOVEL MECHANISM OF TUMOUR SUPPRESSOR GENE INACTIVATION
    Xu, J.
    Reumers, J.
    Couceiro, J.
    Rousseau, F.
    Schymkowitz, J.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S44 - S44